Physician profile
Chandra Veluru
NPI 1750595443
$3,361.70
in general payments reported to CMS, 2019-2025
15 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2022: $218 · 2023: $346 · 2024: $968 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,011.22 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $581.11 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $349.95 | 2024-2025 | Rezdiffra |
| Gilead Sciences, INC. | $249.86 | 2019-2024 | |
| Genzyme Corporation | $244.56 | 2023-2024 | |
| Pfizer INC. | $193.67 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.13 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Alexion Pharmaceuticals, INC. | $113.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $111.80 | 2023 | Dupixent |
| Lilly USA, LLC | $109.42 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $97.87 | 2024-2025 | Entyvio |
| Qol Medical, LLC | $94.32 | 2022 | |
| Braintree Laboratories, INC. | $44.93 | 2024-2025 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $18.25 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $13.94 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Veluru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.